Status: Public Listed (NASDAQ: ADRX)

 

ADARx is developing a modality agnostic RNA targeting platform, including oligonucleotides for inhibition, degradation and editing, together with novel oligonucleotide delivery technologies. They are currently focused on diseases in three therapeutic areas: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases. With RNA as the target of their drug discovery, they are able to work on a wide range of diseases and will continue to add additional disease targets to their pipeline in areas of unmet medical need.

ADARx was listed on NASDAQ in September 2026.

To learn more, please visit: www.adarx.com